Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer -: First results of the randomized Budapest boost trial

被引:0
作者
Polgár, C
Fodor, J
Orosz, Z
Major, T
Takácsi-Nagy, Z
Mangel, LC
Sulyok, Z
Somogyi, A
Kásler, M
Németh, G
机构
[1] Natl Inst Oncol, Dept Radiotherapy, H-1122 Budapest, Hungary
[2] Natl Inst Oncol, Ctr Expt & Human Tumor Pathol, Budapest, Hungary
[3] Natl Inst Oncol, Dept Gen & Thorac Surg, Budapest, Hungary
[4] Semmelweis Univ, Chair Oncol, Budapest, Hungary
关键词
breast cancer; breast-conserving therapy; boost irradiation; electron; brachytherapy; local recurrence;
D O I
10.1007/s00066-002-1053-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Alms: To evaluate the effect of electron and high-dose-rate brachytherapy (HDR BT) boost on Local tumor control (LTC), side effects and cosmesis after breast-conserving surgery (BCS) in a prospective randomized study. Patients and Methods: 207 women with stage I-II breast cancer who underwent BCS were treated by 50 Gy irradiation to the whole breast and then randomly assigned to receive either a boost to the tumor bed (n = 104) or no further radiotherapy (n = 103). Boost treatments consisted of either 16 Gy electron irradiation (n = 52) or 12-14.25 Gy HDR BT (n = 52). Breast cancer-related events, side effects, and cosmetic results were assessed. Results: At a median follow-up of 5.3 years, the crude rate of local recurrence was 6.7% (7/104) with and 15.5% (16/103) without boost. The 5-year probability of LTC, relapse-free survival (RFS), and cancer-specific survival (CSS) was 92.7% vs 84.9% (p = 0.049), 76.6% vs 66.2% (p = 0.044), and 90.4% vs 82.1% (p = 0.053), respectively. There was no significant difference in LTC between patients treated with electron or HDR BT boost (94.2% vs 91.4%; p = 0.74). On multivariate analysis, patient age < 40 years (RR: 4.53), positive margin status (RR: 4.17), and high mitotic activity index (RR: 3.60) were found to be significant risk factors for local recurrence. The incidence of grade 2-3 side effects was higher in the boost arm (17.3% vs 7.8%; p = 0.03). However, the rate of excellent/good cosmetic results was similar for the two arms (85.6% vs 91.3%; p = 0.14). Cosmesis was rated as excellent/good in 88.5% of patients treated with HDR BT and 82.7% of patients with electron boost (p = 0.29). Conclusions: Boost dose significantly improves LTC and RFS in patients treated with BCS and radiotherapy. In spite of the higher incidence of late side effects in the boost arm, boost dose is strongly recommended for patients at high risk for Local recurrence. Positive or close margin status, high mitotic activity index, and young patient age should be viewed as absolute indications for tumor bed boost. LTC and cosmesis are excellent and similar to patients boosted with either HDR BT or electrons.
引用
收藏
页码:615 / 623
页数:9
相关论文
共 69 条
[1]  
[Anonymous], 1981, HIST TYP BREAST TUM
[2]   LOCAL FAILURE AND MARGIN STATUS IN EARLY-STAGE BREAST-CARCINOMA TREATED WITH CONSERVATION SURGERY AND RADIATION-THERAPY [J].
ANSCHER, MS ;
JONES, P ;
PROSNITZ, LR ;
BLACKSTOCK, W ;
HEBERT, M ;
REDDICK, R ;
TUCKER, A ;
DODGE, R ;
LEIGHT, G ;
IGLEHART, JD ;
ROSENMAN, J .
ANNALS OF SURGERY, 1993, 218 (01) :22-28
[3]   Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data [J].
Arriagada, R ;
Le, MG ;
Rochard, F ;
Contesso, G .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1558-1564
[4]   Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. [J].
Bartelink, H ;
Horiot, J ;
Poortmans, P ;
Struikmans, H ;
Van den Bogaert, W ;
Barillot, I ;
Fourquet, A ;
Borger, J ;
Jager, J ;
Hoogenraad, W ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (19) :1378-1387
[5]  
Bayerl A, 2001, STRAHLENTHER ONKOL, V177, P25, DOI 10.1007/PL00002354
[6]  
Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19
[7]   RISK-FACTORS IN BREAST-CONSERVATION THERAPY [J].
BORGER, J ;
KEMPERMAN, H ;
HART, A ;
PETERSE, H ;
VANDONGEN, J ;
BARTELINK, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :653-660
[8]   Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update [J].
Clark, RM ;
Whelan, T ;
Levine, M ;
Roberts, R ;
Willan, A ;
McCulloch, P ;
Lipa, M ;
Wilkinson, RH ;
Mahoney, LJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1659-1664
[9]  
CLARKE DH, 1994, HIGH DOSE RATE BRACH, P321
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187